Academic Journal
Combined 177 Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177 Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability
| العنوان: | Combined 177 Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177 Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability |
|---|---|
| المؤلفون: | Suman, Sonam, Parghane, Rahul V., Joshi, Amit, Prabhash, Kumar, Talole, Sanjay, Basu, Sandip |
| المصدر: | The Prostate ; volume 81, issue 15, page 1225-1234 ; ISSN 0270-4137 1097-0045 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2021 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Objective The aim of present study was to determine and compare the overall response rates, progression‐free survival (PFS), overall survival (OS), and clinical toxicity of the combination of 177Lu‐PSMA‐617 radioligand therapy (PRLT) and abiraterone acetate (AA) versus 177Lu‐PSMA‐617 PRLT as monotherapy in metastatic castration‐resistant prostate cancer (mCRPC) patients. Materials and Methods The mCRPC patients who received at least one cycle of 177 Lu‐PSMA‐617 PRLT with or without AA therapy, were included and analyzed in the present study. The patients were divided into two major groups. Group 1 received only 177 Lu‐PSMA PRLT and Group 2 received combined 177 Lu‐PSMA PRLT + AA therapy. Therapeutic dose of 177 Lu‐PSMA‐617 PRLT was 4.4–5.55 GBq per patient per cycle administered at intervals of 10–12 weeks in both groups. The Group 2 patients additionally received a dose of 1000 mg of AA once daily and 5 mg of prednisone twice daily. Treatment response in two groups was evaluated under four broad categories (a) symptomatic, (b) biochemical (serum prostate‐specific antigen level), (c) objective molecular imaging ( 68 Ga‐PSMA‐11 and 18 F‐FDG PET/CT), and (d) objective anatomical imaging (computed tomography). For assessing treatment response, patients in two groups were categorized into responders (complete response [CR], partial response [PR], and stable disease [SD]) and nonresponders (progressive disease [PD]). The Kaplan–Meier product‐limit method was used to calculate PFS and OS following first 177 Lu‐PSMA PRLT in the two groups. Univariate analysis was used to compare the patients' characteristics in two groups using a χ 2 or Fisher exact test. The Kaplan–Meier curves of PFS and OS between two groups were compared by using the log‐rank test ( p < 0.05 significant). Results A total of 58 mCRPC patients (Group 1, 38 patients and Group 2, 20 patients) were included in this study analysis. The clinical and demographic characteristics of these patients (age, Gleason score, FDG avid disease, metastatic ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/pros.24219 |
| الاتاحة: | http://dx.doi.org/10.1002/pros.24219 https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24219 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/pros.24219 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.945D97F7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/pros.24219 |
|---|